Ads
related to: desloratadine dosage for children by weight
Search results
Results From The WOW.Com Content Network
Clark's rule is a medical term referring to a mathematical formula used to calculate the proper dosage of medicine for children aged 2–17 based on the weight of the patient and the appropriate adult dose. [1] The formula was named after Cecil Belfield Clarke (1894–1970), a Barbadian physician who practiced throughout the UK, the West Indies ...
Desloratadine is used to treat allergic rhinitis, nasal congestion and chronic idiopathic urticaria . [8] It is the major metabolite of loratadine and the two drugs are similar in safety and effectiveness. [8] Desloratadine is available in many dosage forms and under many brand names worldwide. [9]
Dose changes are not required for hepatic or renal impairment. [16] While the onset of its effects vary between formulations, bilastine generally takes effect within 30–60 minutes. [8] It should be taken only by children older than 4 years and adults, or anyone over 12 years for Allertine. [13] [16]
"Desloratadine and pseudoephedrine combination therapy as a comprehensive treatment for allergic rhinitis and nasal congestion". Expert Opin Drug Metab Toxicol . 5 (6): 683–94.
Adverse drug reactions are most commonly associated with the first-generation H 1-antihistamines. This is due to their relative lack of selectivity for the H 1-receptor and their ability to cross the blood–brain barrier. The most common adverse effect is sedation; this "side-effect" is utilized in many OTC sleeping-aid preparations.
Rupatadine fumarate has been approved for the treatment of allergic rhinitis and chronic urticaria in adults and children over 12 years. It is available as round, light salmon coloured tablets containing 10 mg of rupatadine (as fumarate) to be administered orally, once a day.
Ebastine is a H 1 antihistamine with low potential for causing drowsiness.. It does not penetrate the blood–brain barrier to a significant amount and thus combines an effective block of the H 1 receptor in peripheral tissue with a low incidence of central side effects, i.e. seldom causing sedation or drowsiness.
Research on humans ranges from a single 800-mg dose, to a twice-daily, 690-mg dose for a month, with no clinically significant adverse effects, when compared to a placebo. No deaths occurred in testing on mice, at 5000 mg/kg body weight, which is 110 times the maximum recommended dose for an adult human. [ 5 ]